NASDAQ:PCRX Pacira BioSciences (PCRX) Stock Price, News & Analysis $13.85 -0.83 (-5.65%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$13.77▼$14.9050-Day Range$11.70▼$28.4652-Week Range$11.16▼$35.95Volume884,129 shsAverage Volume874,048 shsMarket Capitalization$638.90 millionP/E Ratio9.69Dividend YieldN/APrice Target$24.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Pacira BioSciences alerts: Email Address Pacira BioSciences MarketRank™ Stock AnalysisAnalyst RatingHold2.11 Rating ScoreUpside/Downside78.9% Upside$24.78 Price TargetShort InterestHealthy11.16% of Shares Sold ShortDividend StrengthN/ASustainability-1.89Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$621,118 Sold Last QuarterProj. Earnings Growth-11.61%From $2.24 to $1.98 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.82 out of 5 starsMedical Sector31st out of 910 stocksPharmaceutical Preparations Industry11th out of 426 stocks 4.1 Analyst's Opinion Consensus RatingPacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 3 buy ratings, 4 hold ratings, and 2 sell ratings.Amount of Analyst CoveragePacira BioSciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pacira BioSciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.16% of the outstanding shares of Pacira BioSciences have been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Pacira BioSciences has recently decreased by 18.38%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePacira BioSciences has received a 52.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Bupivacaine", "Cryotherapy devices", and "Drug delivery devices" products. See details.Environmental SustainabilityThe Environmental Impact score for Pacira BioSciences is -1.89. Previous Next 2.8 News and Social Media Coverage News SentimentPacira BioSciences has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pacira BioSciences this week, compared to 4 articles on an average week.Search Interest9 people have searched for PCRX on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have sold 355.90% more of their company's stock than they have bought. Specifically, they have bought $136,240.00 in company stock and sold $621,118.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pacira BioSciences' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Pacira BioSciences are expected to decrease by -11.61% in the coming year, from $2.24 to $1.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 9.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 9.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.06.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pacira BioSciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Pacira BioSciences Stock (NASDAQ:PCRX)Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.Read More PCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCRX Stock News HeadlinesAugust 20, 2024 | insidertrades.comPacira BioSciences, Inc. (NASDAQ:PCRX) Director Marcelo Bigal Acquires 1,512 SharesAugust 14, 2024 | insidertrades.comPacira BioSciences, Inc. (NASDAQ:PCRX) CEO Frank D. Lee Acquires 8,264 SharesSeptember 7, 2024 | Weiss Ratings (Ad)Who are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.August 13, 2024 | insidertrades.comPacira BioSciences, Inc. (NASDAQ:PCRX) Director Mark Froimson Acquires 1,400 SharesAugust 30, 2024 | money.usnews.comPacira BioSciences IncAugust 28, 2024 | americanbankingnews.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by AnalystsAugust 26, 2024 | benzinga.comPacira BioSciences (NASDAQ:PCRX) Stock Quotes, Forecast and News SummaryAugust 24, 2024 | finance.yahoo.comPCRX Sep 2024 22.500 put (PCRX240920P00022500)September 7, 2024 | Weiss Ratings (Ad)Who are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.August 13, 2024 | markets.businessinsider.comSell Rating on Pacira Pharmaceuticals Amid Patent Invalidation and Revenue RisksAugust 13, 2024 | msn.comJP Morgan Downgrades Pacira BioSciences (PCRX)August 12, 2024 | markets.businessinsider.comPacira Pharmaceuticals: Strong Patent Portfolio Defends Against Generics, Undervalued Market Position Prompts Buy RatingAugust 12, 2024 | msn.comPain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear PathAugust 12, 2024 | msn.comPacira downgraded by J.P. Morgan, Piper, RBC, Raymond JamesAugust 9, 2024 | morningstar.comSmall U.S. Stocks Drop; Pacira BioSciences Falls FurthestAugust 9, 2024 | finance.yahoo.comPCRX Jan 2025 30.000 put (PCRX250117P00030000)August 9, 2024 | seekingalpha.comPacira Biosciences plummets 48% as judge rules Exparel patent invalidAugust 9, 2024 | msn.comPacira Biosciences falls as judge rules Exparel patent claim is invalidSee More Headlines Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/30/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PCRX CUSIP69512710 CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees720Year FoundedN/APrice Target and Rating Average Stock Price Target$24.78 High Stock Price Target$57.00 Low Stock Price Target$8.00 Potential Upside/Downside+78.9%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$1.43 Trailing P/E Ratio9.69 Forward P/E Ratio6.18 P/E GrowthN/ANet Income$41.96 million Net Margins9.21% Pretax Margin14.56% Return on Equity13.22% Return on Assets7.24% Debt Debt-to-Equity Ratio0.67 Current Ratio6.82 Quick Ratio5.70 Sales & Book Value Annual Sales$674.98 million Price / Sales0.95 Cash Flow$3.52 per share Price / Cash Flow3.93 Book Value$18.74 per share Price / Book0.74Miscellaneous Outstanding Shares46,130,000Free Float43,567,000Market Cap$638.90 million OptionableOptionable Beta0.84 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Charles A. Reinhart III (Age 63)C.P.A., M.B.A., Chief Financial Officer Comp: $780.58kMr. Daryl Gaugler (Age 62)Chief Operating Officer Comp: $778.77kMs. Kristen Williams J.D. (Age 50)Chief Administrative Officer & Secretary Comp: $799.63kMr. Anthony Molloy III (Age 50)Esq., Chief Legal & Compliance Officer Comp: $581.41kMr. David M. Stack (Age 74)Advisor Comp: $1.54MMr. Frank D. Lee (Age 56)CEO & Director Ms. Lauren Bullaro Riker (Age 45)Principal Accounting Officer & Senior VP of Finance Comp: $288.81kSusan MescoHead of Investor RelationsMr. Richard KahrVice President of Human ResourcesDr. Jonathan Slonin M.D. (Age 49)Chief Medical Officer Comp: $815.25kMore ExecutivesKey CompetitorsAtea PharmaceuticalsNASDAQ:AVIROPKO HealthNASDAQ:OPKADC TherapeuticsNYSE:ADCTSeres TherapeuticsNASDAQ:MCRBSupernus PharmaceuticalsNASDAQ:SUPNView All CompetitorsInsiders & InstitutionsBrown Financial AdvisorsBought 10,323 shares on 8/30/2024Ownership: 0.022%Truist Financial CorpBought 14,798 shares on 8/21/2024Ownership: 0.032%Marcelo BigalBought 1,512 shares on 8/16/2024Total: $20,034.00 ($13.25/share)AQR Capital Management LLCBought 5,918 shares on 8/15/2024Ownership: 0.147%The Manufacturers Life Insurance Company Bought 1,354 shares on 8/15/2024Ownership: 0.052%View All Insider TransactionsView All Institutional Transactions PCRX Stock Analysis - Frequently Asked Questions How have PCRX shares performed this year? Pacira BioSciences' stock was trading at $33.74 on January 1st, 2024. Since then, PCRX stock has decreased by 59.0% and is now trading at $13.85. View the best growth stocks for 2024 here. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its quarterly earnings data on Tuesday, July, 30th. The company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.53 by $0.11. The company had revenue of $178.02 million for the quarter, compared to analyst estimates of $173.31 million. Pacira BioSciences had a trailing twelve-month return on equity of 13.22% and a net margin of 9.21%. What is Dave Stack's approval rating as Pacira BioSciences' CEO? 54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Pacira BioSciences' major shareholders? Top institutional investors of Pacira BioSciences include Pacer Advisors Inc. (4.65%), Renaissance Technologies LLC (4.44%), Dimensional Fund Advisors LP (3.93%) and Doma Perpetual Capital Management LLC (2.17%). Insiders that own company stock include David M Stack, Daryl Gaugler, Kristen Williams, Jonathan Slonin, Roy Winston, Lauren Riker, Charles A Reinhart III, Max Reinhardt, Charles Anthony Laranjeira, Kristen Marie Williams, Lauren Bullaro Riker, Anthony Molloy, Mark A Kronenfeld, Mark Froimson, Marcelo Bigal and John P Phd Longenecker. View institutional ownership trends. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV) and Pfizer (PFE). This page (NASDAQ:PCRX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PCRX Stock Alerts